An androgen receptor N-terminal domain antagonist for treating prostate cancer-Reference-Cited by-同舟云学术

An androgen receptor N-terminal domain antagonist for treating prostate cancer

Published:2013-06-03 Issue:7 Volume:123 Page:2948-2960
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Myung Jae-Kyung,Banuelos Carmen A.,Fernandez Javier Garcia,Mawji Nasrin R.,Wang Jun,Tien Amy H.,Yang Yu Chi,Tavakoli Iran,Haile Simon,Watt Kate,McEwan Iain J.,Plymate Stephen,Andersen Raymond J.,Sadar Marianne D.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference44 articles.

1. Multitude of binding modes attainable by intrinsically disordered proteins: a portrait gallery of disorder-based complexes

2. Small Molecule Inhibitors Targeting the “Achilles' Heel” of Androgen Receptor Activity: Figure 1.

3. In vivo amplification of the androgen receptor gene and progression of human prostate cancer

4. Molecular determinants of resistance to antiandrogen therapy

Cited by 260 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the understanding of androgen receptor structure and function and in the development of next-generation AR-targeted therapeutics;Steroids;2024-10

2. Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer;Steroids;2024-10

3. PROTACing the androgen receptor and other emerging therapeutics in prostate cancer;Expert Review of Anticancer Therapy;2024-07-22

4. Androgen receptor and estrogen receptor variants in prostate and breast cancers;The Journal of Steroid Biochemistry and Molecular Biology;2024-07

5. SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain;Oncogene;2024-03-26